Literature DB >> 16335854

What is potent acid inhibition, and how can it be achieved?

Xavier Calvet1, Fernando Gomollón.   

Abstract

The clinical response to antisecretory treatment correlates directly with the degree of inhibition of acid secretion achieved. Acid inhibition able to maintain the intragastric pH at a value greater than 4 for at least 16 h/day seems to heal even the most refractory acid-related diseases. It has also been shown that the degree of inhibition of acid secretion in response to antisecretory treatment depends on the genetic characteristics of the patient and on the presence of Helicobacter pylori infection. A possible definition of potent (or profound) acid inhibition is, therefore, the achievement of the aforementioned level of control of acid secretion regardless of patient characteristics or of the presence of H. pylori infection. Antisecretory drugs differ in their ability to reach potent acid inhibition. As far as the comparative efficacy of different drugs for inhibiting acid secretion is concerned, proton pump inhibitors are more efficient in inhibiting gastric acid secretion than histamine (H2) receptor antagonists. Among the different proton pump inhibitors, esomeprazole 40 mg/day exhibits greater antisecretory potency than the others at standard doses. Rabeprazole 20 mg/day and lansoprazole 30 mg/day exhibit a more rapid onset of action than omeprazole 20 mg/day or pantoprazole 40 mg/day.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16335854     DOI: 10.2165/00003495-200565001-00004

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  69 in total

1.  Rapid effect of lansoprazole on intragastric pH: a crossover comparison with omeprazole.

Authors:  M Thoring; H Hedenström; L S Eriksson
Journal:  Scand J Gastroenterol       Date:  1999-04       Impact factor: 2.423

2.  Twenty-four-hour intragastric acidity: 300 mg ranitidine b.d., 20 mg omeprazole o.m., 40 mg omeprazole o.m. vs. placebo.

Authors:  G M Houben; J Hooi; W Hameeteman; R W Stockbrügger
Journal:  Aliment Pharmacol Ther       Date:  1995-12       Impact factor: 8.171

3.  Sensitivity of the esophageal mucosa to pH in gastroesophageal reflux disease.

Authors:  J L Smith; A R Opekun; E Larkai; D Y Graham
Journal:  Gastroenterology       Date:  1989-03       Impact factor: 22.682

4.  Effects of CYP2C19 genotypic differences in the metabolism of omeprazole and rabeprazole on intragastric pH.

Authors:  N Shirai; T Furuta; Y Moriyama; H Okochi; K Kobayashi; M Takashima; F Xiao; K Kosuge; K Nakagawa; H Hanai; K Chiba; K Ohashi; T Ishizaki
Journal:  Aliment Pharmacol Ther       Date:  2001-12       Impact factor: 8.171

5.  Effect of esomeprazole 40 mg vs omeprazole 40 mg on 24-hour intragastric pH in patients with symptoms of gastroesophageal reflux disease.

Authors:  Kerstin Röhss; Göran Hasselgren; Hans Hedenström
Journal:  Dig Dis Sci       Date:  2002-05       Impact factor: 3.199

6.  Comparison of lansoprazole and famotidine for gastric acid inhibition during the daytime and night-time in different CYP2C19 genotype groups.

Authors:  N Shirai; T Furuta; F Xiao; M Kajimura; H Hanai; K Ohashi; T Ishizaki
Journal:  Aliment Pharmacol Ther       Date:  2002-04       Impact factor: 8.171

7.  Comparison of lansoprazole with omeprazole on 24-hour intragastric pH, acid secretion and serum gastrin in healthy volunteers.

Authors:  S Bruley des Varannes; P Levy; S Lartigue; F Dellatolas; M Lemaire; J P Galmiche
Journal:  Aliment Pharmacol Ther       Date:  1994-06       Impact factor: 8.171

8.  Twenty-four-hour intragastric pH profiles and pharmacokinetics following single and repeated oral administration of the proton pump inhibitor pantoprazole in comparison to omeprazole.

Authors:  M Hartmann; U Theiss; R Huber; R Lühmann; H Bliesath; W Wurst; P W Lücker
Journal:  Aliment Pharmacol Ther       Date:  1996-06       Impact factor: 8.171

9.  Experimental study of acid burden and acute oesophagitis.

Authors:  K G Pursnani; M A Mohiuddin; K R Geisinger; G Weinbaum; D A Katzka; D O Castell
Journal:  Br J Surg       Date:  1998-05       Impact factor: 6.939

10.  Effects of rabeprazole, 20 mg, or esomeprazole, 20 mg, on 24-h intragastric pH and serum gastrin in healthy subjects.

Authors:  S Warrington; K Baisley; M Boyce; B Tejura; A Morocutti; N Miller
Journal:  Aliment Pharmacol Ther       Date:  2002-07       Impact factor: 8.171

View more
  8 in total

1.  Comparative study of esomeprazole and lansoprazole in triple therapy for eradication of Helicobacter pylori in Japan.

Authors:  Tsutomu Nishida; Masahiko Tsujii; Hirohisa Tanimura; Shusaku Tsutsui; Shingo Tsuji; Akira Takeda; Atsuo Inoue; Hiroyuki Fukui; Toshiyuki Yoshio; Osamu Kishida; Hiroyuki Ogawa; Masahide Oshita; Ichizo Kobayashi; Shinichiro Zushi; Makoto Ichiba; Naoto Uenoyama; Yuichi Yasunaga; Ryu Ishihara; Mamoru Yura; Masato Komori; Satoshi Egawa; Hideki Iijima; Tetsuo Takehara
Journal:  World J Gastroenterol       Date:  2014-04-21       Impact factor: 5.742

2.  Efficacies of different proton pump inhibitor-based 14-day bismuth-furazolidone quadruple regimens for the initial eradication of Helicobacter pylori in the southeast coastal region of China: an open-label, randomized clinical trial.

Authors:  Luyi Chen; Jiamin He; Lan Wang; Qiwei Ge; Hua Chu; Yujia Chen; Xiaoli Chen; Yanqin Long; Yanyong Deng; Huiqin He; Aiqing Li; Shujie Chen
Journal:  Clin Exp Med       Date:  2018-06-06       Impact factor: 3.984

Review 3.  Medical treatment of gastrinomas.

Authors:  Christoph J Auernhammer; Burkhard Göke
Journal:  Wien Klin Wochenschr       Date:  2007       Impact factor: 1.704

4.  Evaluation of Proton Pump Inhibitor Esomeprazole on Crizotinib Pharmacokinetics in Healthy Participants.

Authors:  Huiping Xu; Melissa O'Gorman; Kyle Matschke; Tanya Boutros; Nicoletta Brega; Weiwei Tan; Akintunde Bello
Journal:  Clin Pharmacol Drug Dev       Date:  2021-11-26

Review 5.  The role of pH in symptomatic relief and effective treatment of gastroesophageal reflux disease.

Authors:  Anita Gąsiorowska
Journal:  Prz Gastroenterol       Date:  2017-12-14

6.  Comparative study: Vonoprazan and proton pump inhibitors in Helicobacter pylori eradication therapy.

Authors:  Kouichi Sakurai; Hiroko Suda; Yumi Ido; Takayuki Takeichi; Ayako Okuda; Kiwamu Hasuda; Masahiro Hattori
Journal:  World J Gastroenterol       Date:  2017-01-28       Impact factor: 5.742

7.  Vonoprazan-based triple therapy is effective for Helicobacter pylori eradication irrespective of clarithromycin susceptibility.

Authors:  Hidetaka Okubo; Junichi Akiyama; Masao Kobayakawa; Megumi Kawazoe; Saori Mishima; Yusuke Takasaki; Naoyoshi Nagata; Takayuki Shimada; Chizu Yokoi; Shiori Komori; Kana Kimura; Yuya Hisada; Eri Iwata; Kazuhiro Watanabe; Naohiro Yanagisawa; Sho Shiroma; Akira Shimomura; Koki Okahara; Hourin Cho; Naomi Uemura
Journal:  J Gastroenterol       Date:  2020-09-15       Impact factor: 7.527

8.  Esomeprazole- or rabeprazole-based triple therapy eradicated Helicobacter pylori comparably regardless of clarithromycin susceptibility and CYP2C19 genotypes.

Authors:  Tadayoshi Okimoto; Kazuhiro Mizukami; Ryo Ogawa; Kazuhisa Okamoto; Mitsutaka Shuto; Kensuke Fukuda; Masaaki Kodama; Kazunari Murakami
Journal:  J Clin Biochem Nutr       Date:  2016-07-16       Impact factor: 3.114

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.